Glycans in the immune system and The Altered Glycan Theory of Autoimmunity: A critical review

Journal of Autoimmunity

Volumn 57, Issue , 2015, Pages 1-13

  Maverakis, Emanual ^a   Kim, Kyoungmi ^b   Shimoda, Michiko ^a   Gershwin, M Eric ^a   Patel, Forum ^a   Wilken, Reason ^a   Raychaudhuri, Siba ^a   Ruhaak, L Renee ^b   Lebrilla, Carlito B ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autoimmunity; Glycan; Glycome; Glycosylation; Immunoglobulin

Indexed keywords

CARBOHYDRATE; DANGER ASSOCIATED MOLECULAR PATTERN; GLYCAN; GLYCOME; GLYCOPROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN D; IMMUNOGLOBULIN E; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PROTEIN; SELF ASSOCIATED MOLECULAR PATTERN; UNCLASSIFIED DRUG; IMMUNOGLOBULIN; POLYSACCHARIDE;

ANTIBODY STRUCTURE; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL MIGRATION; GLYCOCALYX; GLYCOSYLATION; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; MASS SPECTROMETRY; MULTIPLE REACTION MONITORING; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; BINDING SITE; BIOLOGICAL MODEL; CYTOLOGY; IMMUNOLOGY; METABOLISM; PATHOLOGY;

AUTOIMMUNE DISEASES; AUTOIMMUNITY; BINDING SITES; GLYCOSYLATION; HUMANS; IMMUNE SYSTEM; IMMUNOGLOBULINS; MODELS, IMMUNOLOGICAL; POLYSACCHARIDES;

EID: 84922887966     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2014.12.002     Document Type: Review

References (117)

1. Parekh R.B., Dwek R.A., Sutton B.J., Fernandes D.L., Leung A., Stanworth D., et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 1985, 316(6027):452-457.
2. Arnold J.N., Wormald M.R., Sim R.B., Rudd P.M., Dwek R.A. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 2007, 25:21-50.
3. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 2009, 8(3):226-234.
4. Ravetch J.V., Bolland S. IgG Fc receptors. Annu Rev Immunol 2001, 19:275-290.
5. Rock B., Martins C.R., Theofilopoulos A.N., Balderas R.S., Anhalt G.J., Labib R.S., et al. The pathogenic effect of IgG4 autoantibodies in endemic pemphigus foliaceus (fogo selvagem). NEngl J Med 1989, 320(22):1463-1469.
6. Kamisawa T., Funata N., Hayashi Y., Eishi Y., Koike M., Tsuruta K., et al. Anewclinicopathological entity of IgG4-related autoimmune disease. JGastroenterol 2003, 38(10):982-984.
7. Apweiler R., Hermjakob H., Sharon N. On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database. Biochim BiophysActa 1999, 1473(1):4-8.
8. Transforming glycoscience: a roadmap for the future 2012, Washington (DC).
9. Cummings R.D. The repertoire of glycan determinants in the human glycome. Mol Biosyst 2009, 5(10):1087-1104.
10. Smith D.F., Cummings R.D. Application of microarrays for deciphering thestructure and function of the human glycome. Mol Cell Proteomics 2013, 12(4):902-912.
11. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994, 12:991-1045.
12. Medzhitov R., Preston-Hurlburt P., Janeway C.A. Ahuman homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997, 388(6640):394-397.
13. Medzhitov R., Janeway C.A. Innate immunity: the virtues of a nonclonal system of recognition. Cell 1997, 91(3):295-298.
14. Gallucci S., Matzinger P. Danger signals: SOS to the immune system. Curr Opin Immunol 2001, 13(1):114-119.
15. Banda N.K., Takahashi M., Takahashi K., Stahl G.L., Hyatt S., Glogowska M., et al. Mechanisms of mannose-binding lectin-associated serine proteases-1/3 activation of the alternative pathway of complement. Mol Immunol 2011, 49(1-2):281-289.
16. Lehrer R.I., Jung G., Ruchala P., Andre S., Gabius H.J., Lu W. Multivalent binding of carbohydrates by the human alpha-defensin, HD5. JImmunol 2009, 183(1):480-490.
17. Varki A., Gagneux P. Human-specific evolution of sialic acid targets: explaining the malignant malaria mystery?. Proc Natl Acad Sci U S A 2009, 106(35):14739-14740.
18. Chen H.Y., Fermin A., Vardhana S., Weng I.C., Lo K.F., Chang E.Y., et al. Galectin-3 negatively regulates TCR-mediated CD4+ T-cell activation at the immunological synapse. Proc Natl Acad Sci U S A 2009, 106(34):14496-14501.
19. Pillai S., Netravali I.A., Cariappa A., Mattoo H. Siglecs and immune regulation. Annu Rev Immunol 2012, 30:357-392.
20. Geijtenbeek T.B., van Vliet S.J., Engering A., t Hart B.A., van Kooyk Y. Self- and nonself-recognition by C-type lectins on dendritic cells. Annu Rev Immunol 2004, 22:33-54.
21. Steinman R.M., Hawiger D., Nussenzweig M.C. Tolerogenic dendritic cells. Annu Rev Immunol 2003, 21:685-711.
22. Carlin A.F., Uchiyama S., Chang Y.C., Lewis A.L., Nizet V., Varki A. Molecular mimicry of host sialylated glycans allows a bacterial pathogen to engage neutrophil Siglec-9 and dampen the innate immuneresponse. Blood 2009, 113(14):3333-3336.
23. Khatua B., Ghoshal A., Bhattacharya K., Mandal C., Saha B., Crocker P.R., et al. Sialic acids acquired by Pseudomonas aeruginosa are involved in reduced complement deposition and siglec mediated host-cell recognition. FEBS Lett 2010, 584(3):555-561.
24. Ashwell G., Harford J. Carbohydrate-specific receptors of the liver. Annu Rev Biochem 1982, 51:531-554.
25. Aminoff D., Bruegge W.F., Bell W.C., Sarpolis K., Williams R. Role of sialic acid in survival of erythrocytes in the circulation: interaction of neuraminidase-treated and untreated erythrocytes with spleen and liver at the cellular level. Proc Natl Acad Sci U S A 1977, 74(4):1521-1524.
26. Earl L.A., Bi S., Baum L.G. N- and O-glycans modulate galectin-1 binding, CD45 signaling, and T cell death. JBiol Chem 2010, 285(4):2232-2244.
27. Toscano M.A., Bianco G.A., Ilarregui J.M., Croci D.O., Correale J., Hernandez J.D., et al. Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nat Immunol 2007, 8(8):825-834.
28. Basset C., Devauchelle V., Durand V., Jamin C., Pennec Y.L., Youinou P., et al. Glycosylation of immunoglobulin A influences its receptor binding. Scand J Immunol 1999, 50(6):572-579.
29. Stockert R.J. The asialoglycoprotein receptor: relationships between structure, function, and expression. Physiol Rev 1995, 75(3):591-609.
30. Hiki Y., Odani H., Takahashi M., Yasuda Y., Nishimoto A., Iwase H., et al. Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy. Kidney Int 2001, 59(3):1077-1085.
31. Kokubo T., Hiki Y., Iwase H., Tanaka A., Toma K., Hotta K., et al. Protective role of IgA1 glycans against IgA1 self-aggregation and adhesion to extracellular matrix proteins. JAm Soc Nephrol 1998, 9(11):2048-2054.
32. Ghetie V., Ward E.S. Multiple roles for the major histocompatibility complex class I- related receptor FcRn. Annu Rev Immunol 2000, 18:739-766.
33. Roopenian D.C., Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007, 7(9):715-725.
34. Sallusto F., Lenig D., Forster R., Lipp M., Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999, 401(6754):708-712.
35. Fuhlbrigge R.C., Kieffer J.D., Armerding D., Kupper T.S. Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells. Nature 1997, 389(6654):978-981.
36. Vestweber D., Blanks J.E. Mechanisms that regulate the function of the selectins and their ligands. Physiol Rev 1999, 79(1):181-213.
37. Carroll M.C. The complement system in regulation of adaptive immunity. Nat Immunol 2004, 5(10):981-986.
38. Nimmerjahn F., Ravetch J.V. Fcgamma receptors: old friends and new family members. Immunity 2006, 24(1):19-28.
39. Nimmerjahn F., Ravetch J.V. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008, 26:513-533.
40. Rosales C., Uribe-Querol E. Fc receptors: cell activators of antibody functions. Adv Biosci Biotechnol 2013, 4:21-33.
41. Daeron M. Fc receptor biology. Annu Rev Immunol 1997, 15:203-234.
42. Hulett M.D., Hogarth P.M. Molecular basis of Fc receptor function. Adv Immunol 1994, 57:1-127.
43. Kocher M., Siegel M.E., Edberg J.C., Kimberly R.P. Cross-linking of Fc gamma receptor IIa and Fc gamma receptorIIIb induces different proadhesive phenotypes on human neutrophils. JImmunol 1997, 159(8):3940-3948.
44. Rivas-Fuentes S., Garcia-Garcia E., Nieto-Castaneda G., Rosales C. Fcgamma receptors exhibit different phagocytosis potential in human neutrophils. Cell Immunol 2010, 263(1):114-121.
45. Garcia-Garcia E., Nieto-Castaneda G., Ruiz-Saldana M., Mora N., Rosales C. FcgammaRIIA and FcgammaRIIIB mediate nuclear factor activation through separate signaling pathways in human neutrophils. JImmunol 2009, 182(8):4547-4556.
46. Ortiz-Stern A., Rosales C. Fc gammaRIIIB stimulation promotes beta1 integrin activation in human neutrophils. JLeukoc Biol 2005, 77(5):787-799.
47. Bolland S., Ravetch J.V. Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis. Immunity 2000, 13(2):277-285.
48. De Graaf T.W., Van der Stelt M.E., Anbergen M.G., van Dijk W. Inflammation-induced expression of sialyl Lewis X-containing glycan structures on alpha 1-acid glycoprotein (orosomucoid) in human sera. JExp Med 1993, 177(3):657-666.
49. Azuma Y., Murata M., Matsumoto K. Alteration of sugar chains on alpha(1)-acid glycoprotein secreted following cytokine stimulation of HuH-7 cells invitro. Clin Chim Acta 2000, 294(1-2):93-103.
50. Gabay C., Kushner I. Acute-phase proteins and other systemic responses to inflammation. NEngl J Med 1999, 340(6):448-454.
51. Ackerman M.E., Crispin M., Yu X., Baruah K., Boesch A.W., Harvey D.J., et al. Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. JClin Invest 2013, 123(5):2183-2192.
52. Thompson S., Dargan E., Griffiths I.D., Kelly C.A., Turner G.A. The glycosylation of haptoglobin in rheumatoid arthritis. Clin Chim Acta 1993, 220(1):107-114.
53. Goodarzi M.T., Turner G.A. Reproducible and sensitive determination of charged oligosaccharides from haptoglobin by PNGase F digestion and HPAEC/PAD analysis: glycan composition varies with disease. Glycoconj J 1998, 15(5):469-475.
54. Parekh R.B., Roitt I.M., Isenberg D.A., Dwek R.A., Ansell B.M., Rademacher T.W. Galactosylation of IgG associated oligosaccharides: reduction in patients with adult and juvenile onset rheumatoid arthritis and relation to disease activity. Lancet 1988, 1(8592):966-969.
55. Moore J.S., Wu X., Kulhavy R., Tomana M., Novak J., Moldoveanu Z., et al. Increased levels of galactose-deficient IgG in sera of HIV-1-infected individuals. AIDS 2005, 19(4):381-389.
56. Holland M., Yagi H., Takahashi N., Kato K., Savage C.O., Goodall D.M., et al. Differential glycosylation of polyclonal IgG, IgG-Fc and IgG-Fab isolated from the sera of patients with ANCA-associated systemic vasculitis. Biochim Biophys Acta 2006, 1760(4):669-677.
57. Homma H., Tozawa K., Yasui T., Itoh Y., Hayashi Y., Kohri K. Abnormal glycosylation of serum IgG in patients with IgA nephropathy. Clin Exp Nephrol 2006, 10(3):180-185.
58. Saldova R., Royle L., Radcliffe C.M., Abd Hamid U.M., Evans R., Arnold J.N., et al. Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. Glycobiology 2007, 17(12):1344-1356.
59. Selman M.H., Niks E.H., Titulaer M.J., Verschuuren J.J., Wuhrer M., Deelder A.M. IgG fc N-glycosylation changes in Lambert-Eaton myasthenic syndrome and myasthenia gravis. JProteome Res 2011, 10(1):143-152.
60. Kodar K., Stadlmann J., Klaamas K., Sergeyev B., Kurtenkov O. Immunoglobulin G Fc N-glycan profiling in patients with gastric cancer by LC-ESI-MS: relation to tumor progression and survival. Glycoconj J 2012, 29(1):57-66.
61. Selman M.H., de Jong S.E., Soonawala D., Kroon F.P., Adegnika A.A., Deelder A.M., et al. Changes in antigen-specific IgG1 Fc N-glycosylation upon influenza and tetanus vaccination. Mol Cell Proteomics 2012, 11(4). p. M111 014563.
62. Ruhaak L.R., Nguyen U.T., Stroble C., Taylor S.L., Taguchi A., Hanash S.M., et al. Enrichment strategies in glycomics-based lung cancer biomarker development. Proteomics Clin Appl 2013, [Epub ahead of print]. 10.1002/prca.201200131.
63. Parekh R., Isenberg D., Rook G., Roitt I., Dwek R., Rademacher T. Acomparative analysis of disease-associated changes in the galactosylation of serum IgG. JAutoimmun 1989, 2(2):101-114.
64. Bond A., Alavi A., Axford J.S., Bourke B.E., Bruckner F.E., Kerr M.A., et al. Adetailed lectin analysis of IgG glycosylation, demonstrating disease specific changes in terminal galactose and N-acetylglucosamine. JAutoimmun 1997, 10(1):77-85.
65. Mimura Y., Sondermann P., Ghirlando R., Lund J., Young S.P., Goodall M., et al. Role of oligosaccharide residues of IgG1-Fc in Fc gamma RIIb binding. JBiol Chem 2001, 276(49):45539-45547.
66. Lund J., Takahashi N., Pound J.D., Goodall M., Jefferis R. Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharide chains. JImmunol 1996, 157(11):4963-4969.
67. Okazaki A., Shoji-Hosaka E., Nakamura K., Wakitani M., Uchida K., Kakita S., et al. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa. JMol Biol 2004, 336(5):1239-1249.
68. Ferrara C., Stuart F., Sondermann P., Brunker P., Umana P. The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. JBiol Chem 2006, 281(8):5032-5036.
69. Rook G.A., Steele J., Brealey R., Whyte A., Isenberg D., Sumar N., et al. Changes in IgG glycoform levels are associated with remission of arthritis during pregnancy. JAutoimmun 1991, 4(5):779-794.
70. Axford J.S., Mackenzie L., Lydyard P.M., Hay F.C., Isenberg D.A., Roitt I.M. Reduced B-cell galactosyltransferase activity in rheumatoid arthritis. Lancet 1987, 2(8574):1486-1488.
71. Axford J.S., Sumar N., Alavi A., Isenberg D.A., Young A., Bodman K.B., et al. Changes in normal glycosylation mechanisms in autoimmune rheumatic disease. JClin Invest 1992, 89(3):1021-1031.
72. Malhotra R., Wormald M.R., Rudd P.M., Fischer P.B., Dwek R.A., Sim R.B. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat Med 1995, 1(3):237-243.
73. Garred P., Madsen H.O., Marquart H., Hansen T.M., Sorensen S.F., Petersen J., et al. Two edged role of mannose binding lectin in rheumatoid arthritis: a cross sectional study. JRheumatol 2000, 27(1):26-34.
74. Banda N.K., Wood A.K., Takahashi K., Levitt B., Rudd P.M., Royle L., et al. Initiation of the alternative pathway of murine complement by immune complexes is dependent on N-glycans in IgG antibodies. Arthritis Rheum 2008, 58(10):3081-3089.
75. Parekh R., Roitt I., Isenberg D., Dwek R., Rademacher T. Age-related galactosylation of the N-linked oligosaccharides of human serum IgG. JExp Med 1988, 167(5):1731-1736.
76. Kaneko Y., Nimmerjahn F., Ravetch J.V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006, 313(5787):670-673.
77. Anthony R.M., Wermeling F., Karlsson M.C., Ravetch J.V. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci U S A 2008, 105(50):19571-19578.
78. Fehr J., Hofmann V., Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. NEngl J Med 1982, 306(21):1254-1258.
79. Imbach P., Barandun S., Baumgartner C., Hirt A., Hofer F., Wagner H.P. High-dose intravenous gammaglobulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood. Helv Paediatr Acta 1981, 36(1):81-86.
80. Bruhns P., Samuelsson A., Pollard J.W., Ravetch J.V. Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity 2003, 18(4):573-581.
81. Tackenberg B., Jelcic I., Baerenwaldt A., Oertel W.H., Sommer N., Nimmerjahn F., et al. Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc Natl Acad Sci U. S. A 2009, 106(12):4788-4792.
82. Hansen R.J., Balthasar J.P. Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia. Blood 2002, 100(6):2087-2093.
83. Watier H. Variability factors in the clinical response to recombinant antibodiesand IgG Fc-containing fusion proteins. Expert Opin Biol Ther 2005, 5(Suppl.1):S29-S36.
84. Marcus R., Hagenbeek A. The therapeutic use of rituximab in non-Hodgkin's lymphoma. Eur J Haematol Suppl 2007, 67:5-14.
85. Lifely M.R., Hale C., Boyce S., Keen M.J., Phillips J. Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions. Glycobiology 1995, 5(8):813-822.
86. Umana P., Jean-Mairet J., Moudry R., Amstutz H., Bailey J.E. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 1999, 17(2):176-180.
87. Davies J., Jiang L., Pan L.Z., LaBarre M.J., Anderson D., Reff M. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII. Biotechnol Bioeng 2001, 74(4):288-294.
88. Niwa R., Natsume A., Uehara A., Wakitani M., Iida S., Uchida K., et al. IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. JImmunol Methods 2005, 306(1-2):151-160.
89. Imai-Nishiya H., Mori K., Inoue M., Wakitani M., Iida S., Shitara K., et al. Double knockdown of alpha1,6-fucosyltransferase (FUT8) and GDP-mannose 4,6-dehydratase (GMD) in antibody-producing cells: a new strategy for generating fully non-fucosylated therapeutic antibodieswith enhanced ADCC. BMC Biotechnol 2007, 7:84.
90. Yamane-Ohnuki N., Kinoshita S., Inoue-Urakubo M., Kusunoki M., Iida S., Nakano R., et al. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng 2004, 87(5):614-622.
91. An H.J., Ninonuevo M., Aguilan J., Liu H., Lebrilla C.B., Alvarenga L.S., et al. Glycomics analyses of tear fluid for the diagnostic detection of ocular rosacea. JProteome Res 2005, 4(6):1981-1987.
92. An H.J., Miyamoto S., Lancaster K.S., Kirmiz C., Li B., Lam K.S., et al. Profiling of glycans in serum for the discovery of potential biomarkers for ovarian cancer. JProteome Res 2006, 5(7):1626-1635.
93. An H.J., Kronewitter S.R., de Leoz M.L., Lebrilla C.B. Glycomics and disease markers. Curr Opin Chem Biol 2009, 13(5-6):601-607.
94. Kronewitter S.R., de Leoz M.L., Peacock K.S., McBride K.R., An H.J., Miyamoto S., et al. Human serum processing and analysis methods for rapid and reproducible N-glycan mass profiling. JProteome Res 2010, 9(10):4952-4959.
95. Kronewitter S.R., De Leoz M.L., Strum J.S., An H.J., Dimapasoc L.M., Guerrero A., et al. The glycolyzer: automated glycan annotation software for high performance mass spectrometry and its application to ovarian cancer glycan biomarker discovery. Proteomics 2012, 12(15-16):2523-2538.
96. Hong Q., Lebrilla C.B., Miyamoto S., Ruhaak L.R. Absolute quantitation of immunoglobulin G and its glycoforms using multiple reaction monitoring. Anal Chem 2013, 85(18):8585-8593.
97. Li A.C., Alton D., Bryant M.S., Shou W.Z. Simultaneously quantifying parent drugs and screening for metabolites in plasma pharmacokinetic samples using selected reaction monitoring information-dependent acquisition on a QTrap instrument. Rapid Commun Mass Spectrom 2005, 19(14):1943-1950.
98. Xiao J.F., Zhou B., Ressom H.W. Metabolite identification and quantitation in LC-MS/MS-based metabolomics. Trends Anal Chem 2012, 32:1-14.
99. Kitteringham N.R., Jenkins R.E., Lane C.S., Elliott V.L., Park B.K. Multiple reaction monitoring for quantitative biomarker analysis in proteomics and metabolomics. JChromatogr B Analyt Technol Biomed Life Sci 2009, 877(13):1229-1239.
100. Gallien S., Duriez E., Domon B. Selected reaction monitoring applied to proteomics. JMass Spectrom 2011, 46(3):298-312.
101. Querol L., Nogales-Gadea G., Rojas-Garcia R., Diaz-Manera J., Pardo J., Ortega-Moreno A., et al. Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. Neurology 2014, 82(10):879-886.
102. Zhang J., Zhao L., Gao Y., Liu M., Li T., Huang Y., et al. Aclassification of Hashimoto's thyroiditis based on immunohistochemistry for IgG4 and IgG. Thyroid 2014, 24(2):364-370.
103. Dhandha M.M., Seiffert-Sinha K., Sinha A.A. Specific immunoglobulin isotypes correlate with disease activity, morphology, duration and HLA association in Pemphigus vulgaris. Autoimmunity 2012, 45(7):516-526.
104. Liu H., Peng Y., Liu F., Xiao W., Zhang Y., Li W. Expression of IgA class switching gene in tonsillar mononuclear cells in patients with IgA nephropathy. Inflamm Res 2011, 60(9):869-878.
105. de Haan S., Lahooti H., Morris O., Wall J.R. Epitopes, immunoglobulin classes and immunoglobulin G subclasses of calsequestrin antibodies in patients with thyroid eye disease. Autoimmunity 2010, 43(8):698-703.
106. Santoh T., Watanabe M., Kuroda S., Ueda D., Iwatani Y. Ratio of serum IgG3 to total IgG concentration and goiter size are independent factors in intractability of Graves' disease. Endocr J 2007, 54(6):887-894.
107. Lleo A., Liao J., Invernizzi P., Zhao M., Bernuzzi F., Ma L., et al. Immunoglobulin M levels inversely correlate with CD40 ligand promoter methylation in patients with primary biliary cirrhosis. Hepatology 2012, 55(1):153-160.
108. Rigopoulou E.I., Davies E.T., Pares A., Zachou K., Liaskos C., Bogdanos D.P., et al. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. Gut 2005, 54(4):528-532.
109. Scherer H.U., van der Woude D., Ioan-Facsinay A., el Bannoudi H., Trouw L.A., Wang J., et al. Glycan profiling of anti-citrullinated protein antibodies isolated from human serum and synovial fluid. Arthritis Rheum 2010, 62(6):1620-1629.
110. Matsumoto A., Shikata K., Takeuchi F., Kojima N., Mizuochi T. Autoantibody activity of IgG rheumatoid factor increases with decreasing levels of galactosylation and sialylation. JBiochem 2000, 128(4):621-628.
111. Novak J., Moldoveanu Z., Renfrow M.B., Yanagihara T., Suzuki H., Raska M., et al. IgA nephropathy and Henoch-Schoenlein purpura nephritis: aberrant glycosylation of IgA1, formation of IgA1-containing immune complexes, and activation of mesangial cells. Contrib Nephrol 2007, 157:134-138.
112. Mestecky J., Tomana M., Crowley-Nowick P.A., Moldoveanu Z., Julian B.A., Jackson S. Defective galactosylation and clearance of IgA1 molecules as a possible etiopathogenic factor in IgA nephropathy. Contrib Nephrol 1993, 104:172-182.
113. Mestecky J., Tomana M., Moldoveanu Z., Julian B.A., Suzuki H., Matousovic K., et al. Role of aberrant glycosylation of IgA1 molecules in the pathogenesis of IgA nephropathy. Kidney Blood Press Res 2008, 31(1):29-37.
114. Allen A.C., Harper S.J., Feehally J. Galactosylation of N- and O-linked carbohydrate moieties of IgA1 and IgG in IgA nephropathy. Clin Exp Immunol 1995, 100(3):470-474.
115. Holland M., Takada K., Okumoto T., Takahashi N., Kato K., Adu D., et al. Hypogalactosylation of serum IgG in patients with ANCA-associated systemic vasculitis. Clin Exp Immunol 2002, 129(1):183-190.
116. Espy C., Morelle W., Kavian N., Grange P., Goulvestre C., Viallon V., et al. Sialylation levels of anti-proteinase 3 antibodies are associated with the activity of granulomatosis with polyangiitis (Wegener's). Arthritis Rheum 2011, 63(7):2105-2115.
117. Youinou P., Pennec Y.L., Casburn-Budd R., Dueymes M., Letoux G., Lamour A. Galactose terminating oligosaccharides of IgG in patients with primary Sjogren's syndrome. JAutoimmun 1992, 5(3):393-400.